Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease
NCT ID: NCT04569825
Last Updated: 2020-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
250 participants
INTERVENTIONAL
2020-08-01
2020-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective: To estimate the efficacy of local steroid in the treatment of anosmia in COVID-19 patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: To estimate the efficacy of local steroid in the treatment of anosmia in COVID-19 patients.
Materials and Methods: A double-blinded randomized controlled trial was conducted at Al-Ramadi Teaching Hospital and Tikrit Teaching Hospital during the period from 23th August to 30th September. Proven cases by real-time polymerase chain reaction and presented with anosmia alone or with ageusia were enrolled in the study. The patients divided into 4 groups according to the treatment modalities. Group A (local steroid nasal drops), group B (local normal saline nasal drops), group C (systemic and local steroid), and group D (systemic steroid and local normal saline). Comparison between the groups concerning the fate and the recovery time of the anosmia was analyzed.
Results and Conclusion: Depends on the finding of the studied patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Local Nasal Steroid
Application of Local Nasal Steroid for the COVID-19 patients with anosmia
Ophtamesone
local application intranasally as drops
Normal Saline
Application of Normal Saline for the COVID-19 patients with anosmia
Ophtamesone
local application intranasally as drops
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ophtamesone
local application intranasally as drops
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Of Anbar
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Raid M. Al-Ani
Proffesor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raid M Al-Ani, FIBMS (ENT)
Role: PRINCIPAL_INVESTIGATOR
University Of Anbar
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Raid Muhmid Al-Ani
Ramadi, Al Anbar, Iraq
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Raid M Al-Ani, FIBMS (ENT)
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Webster KE, O'Byrne L, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD013877. doi: 10.1002/14651858.CD013877.pub3.
O'Byrne L, Webster KE, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD013876. doi: 10.1002/14651858.CD013876.pub3.
Rashid RA, Zgair A, Al-Ani RM. Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study. Am J Otolaryngol. 2021 Sep-Oct;42(5):103033. doi: 10.1016/j.amjoto.2021.103033. Epub 2021 Apr 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1148
Identifier Type: -
Identifier Source: org_study_id